Pipeline Built for Controlled Immune Activation, Clinical Impact and Expansion Across Cancer Treatment Modalities
Aptevo Therapeutics is advancing a differentiated oncology pipeline grounded in multispecific antibody engineering and designed to harness immune activation with precision. Led by clinical proof-of-concept in acute myeloid leukemia and supported by next-generation bispecific and trispecific programs, Aptevo’s pipeline is built to address urgent unmet needs while creating multiple paths for clinical and strategic value creation.
The Company’s proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms enable novel mechanisms of action that engage multiple immune pathways with the control needed to support safety, combinability with existing standards of care and expansion into emerging treatment approaches, including radiopharmaceutical combinations. Through this approach, Aptevo is working to advance therapies that may broaden what is possible for patients with difficult-to-treat hematologic cancers and solid tumors.
